The important roles of CXCR4 in multiple diseases have encouraged the development of clinically viable CXCR4 antagonists, and resulted in the US Food and Drug Administration (FDA) approval of the first CXCR4 antagonist, plerixafor for patients with non-Hodgkin's lymphoma and multiple myeloma [2]. This evidence concerns the gene CXCR4 and non-Hodgkin lymphoma.